Skip to content
A uterine cancer survivor and her son stand in front of a flowing river.

Ovarian Cancer Research Alliance

OCRA to Host FDA Listening Session at International Gynecologic Cancer Conference®

Submit your questions ahead of this important conversation with leaders from the U.S. Food and Drug Administration, and register to join us for the free online conference taking place September 16–17.

Woman's image in Discovery Lab of Community Accelerated Research Exchange

A New Way to Move Gynecologic Cancer Research Forward

OCRA's Research Exchange is a first-of-its-kind, global, AI-powered ecosystem designed to transform how gynecologic cancer research is conducted—accelerating breakthroughs by connecting patients, clinicians, researchers, and data in real time. Whether you’re sharing your experience in our patient registry, exploring new findings, reading last month’s gyn cancer journal articles, or supporting this work, you can participate.

Only OCRA combines a laser focus with a panoramic view.

Funding Breakthrough Research

OCRA has invested $140 million toward finding a cure for ovarian and gynecologic cancers.

Discover our research

Supporting You Every Step of The Way

OCRA’s groundbreaking programs help 140,000 people each year navigate an overwhelming diagnosis, aiding patients and families when they need it most.

Find support

Advocacy is the Lifeblood of Change

OCRA advocates on Capitol Hill to improve research and education, drug and diagnostic safety, and access to quality care for all members of the ovarian and gynecologic cancer community. To date, OCRA has helped secure more than $3.8 billion in federal funding.

Take action now
A woman wearing sunglasses and a gray shirt kisses a small child on the lips. The child, dressed in a yellow shirt with a Disney character and a yellow bow in her hair, looks content. They are outdoors with trees and greenery in the background.

Genetic testing can save your life.

Knowledge is power. Genetic testing can lower your risk of ovarian and gynecologic cancers.

The power of shared experiences

Join our Staying Connected Support Series, Woman to Woman Peer Mentor Program, or online community for knowledge, connection, support, and hope.

A Message from President and CEO Audra Moran

Get Involved

Join us as we drive innovation, offer hope, and invest in groundbreaking research that saves lives.

There are so many ways to lend a hand and improve the lives of thousands of ovarian and gynecologic cancer patients and their families.

News & Updates

September is Gynecologic and Ovarian Cancer Awareness Month

September is Gynecologic and Ovarian Cancer Awareness Month

About Gynecologic and Ovarian Cancer Awareness Month September is recognized nationwide as Gynecologic and Ovarian Cancer Awareness Month, a dedicated time to raise awareness for all gynecologic cancers. Throughout the month, OCRA joins forces with patients, caregivers, and supporters to amplify our voices. We focus on educating the public about risks and symptoms, highlighting the … Continued

Read more

The Overview: July 2026

The Overview: July 2026

SummeRun Raises $260,000+ for Research, Hope and Progress Nearly one thousand runners, walkers, survivors, families, friends, and supporters showed up at Seattle’s Seward Park on Sunday, July 12th, for the 33rd annual Ovarian Cancer Research Alliance (OCRA) Rivkin Family SummeRun, raising more than $260,000 for research and programs that support the gynecologic cancer community. The … Continued

Read more

Navigating Platinum-Resistant Ovarian Cancer: Everyday Health Shares Coping Strategies and OCRA Resources

Navigating Platinum-Resistant Ovarian Cancer: Everyday Health Shares Coping Strategies and OCRA Resources

In an article published by Everyday Health, “Coping With the Emotional Challenges of Platinum-Resistant Ovarian Cancer” (June 10, 2026), Ovarian Cancer Research Alliance (OCRA) community member Amanda Widro shares her experience navigating a platinum-resistant ovarian cancer diagnosis. Ovarian cancer is considered platinum-resistant when it recurs within six months of finishing platinum-based chemotherapy. Widro, who was … Continued

Read more

Stay Informed

Get email updates about research news, action alerts, and ways to join the fight.

Our website uses cookies to ensure you get the best experience. By continuing to use this website, you indicate that you have read and agree to our Terms of Use and Privacy Policy.